Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  • Hugo Vachon
  • Justyna Mierzynska
  • Mekdes Taye
  • Madeline Pe
  • Corneel Coens
  • Francesca Martinelli
  • Catherine Fortpied
  • Henning-Hans Flechtner
  • Maja Vestmoe Maraldo
  • Martin Hutchings
  • Paul Meijnders
  • Berthe Aleman
  • Pieternella Lugtenburg
  • Michele Spina
  • Marc André
  • Mark Hertzberg
  • Javier Briones
  • Andrew Bottomley
  • EORTC Quality of Life Group, Lymphoma Group
View graph of relations

OBJECTIVES: To provide reference values for the European Organisation for Treatment and Research of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in advanced-stage Hodgkin lymphoma (HL) patients and 5-year HL survivors. The QLQ-C30 is the most widely used cancer-specific questionnaire to assess Health-Related Quality of Life (HRQoL).

METHODS: The EORTC database was searched to identify HL RCTs in which patients' and survivors' HRQoL was assessed by the QLQ-C30. HRQoL mean scores were calculated and stratified by age and gender. Minimal important differences were used to assess the clinical relevance of the findings. Data from one RCT with HRQoL scores available at baseline (n = 343) and four RCTs with HRQoL scores available at follow-up (n = 1665) were analyzed.

RESULTS: Patients reported worse HRQoL scores than survivors across most functioning scales and symptoms' scales. These scores varied as a function of gender but not age. Survivors' HRQoL reports were comparable to the ones of the general population.

CONCLUSIONS: These values provide an assessment framework for the comparison and interpretation of QLQ-C30 scores in advanced-stage HL. Our findings suggest that although HL patients' HRQoL scores are worse than the general population, HRQoL scores may normalize over long-term survival.

Original languageEnglish
JournalEuropean Journal of Haematology
Issue number5
Pages (from-to)697-707
Number of pages11
Publication statusPublished - May 2021

    Research areas

  • EORTC QLQ-C30, Hodgkin lymphoma - survivor, quality of life, reference values, C30, EORTC QLQ&#8208, Hodgkin lymphoma &#8208, survivor

ID: 62111053